Now Available
New Nutraceutical Product
Sublingual Sodium Selenite Tablets
Therapeutic Level Dose
Please contact us to place an order.
A message from the Founder and Director of the
Nutritional Oncology Research Institute:
February 1, 2012
Greetings,
Over 30 years of solid scientific evidence supports the use of selenium and more specifically, sodium selenite, as a selective chemotherapeutic agent. In other words, sodium selenite is able to induce death in cancer cells while causing no harm to normal healthy cells. Why this scientifically validated fact has been buried for over three decades is a mystery. Or, maybe not. There is no money in this for pharmaceutical companies and the medical establishment.
A study published in 1981 by John Milner demonstrated that sodium selenite killed leukemia cells in mice while causing no harm to normal cells or organs. Within the conclusion of the study, the author suggested that there was sufficient evidence to begin human clinical trials using sodium selenite as a selective chemotherapeutic agent. A study, five years later, demonstrated the same effect for breast cancer. Subsequent studies have confirmed the effect for many other forms of cancer in cell culture, animal and human experimental models.
The Nutritional Oncology Research Institute is actively investigating the use of sodium selenite as a selective chemotherapeutic agent in human clinical studies. Our findings, so far, indicate that sodium selenite at high doses is a very safe and effective nutritional supplement that has the ability to kill cancer cells without any adverse side effects. High dose sodium selenite has been demonstrated to be effective for a wide variety of cancers. The scientific evidence supports the use of sodium selenite for treating lung, colon, breast, brain, bone, liver, skin, blood, prostate, cervical and stomach cancers.
Specific forms of selenium have demonstrated potent chemopreventive effects in human clinical studies. 200 micrograms of selenized yeast as a daily supplement reduced the incidence of colon, lung and prostate cancer by over 50%. This study was the NPC trial published in 1996 by Clark. The more current SELECT trial failed to detect any benefit from selenium supplementation for preventing cancer. A different form of selenium was used than the previous NPC trial. The lesson here is that the specific form of selenium is very critical for prevention or therapeutic effects on cancer.
It is logical that the most potent compound discovered and extensively studied for the prevention of cancer is also the most potent, safe and effective compound for treating cancer. The only difference is in the required dose and route of administration.
The Nutritional Oncology Research Institute is pleased to offer professional training on the high dose sodium selenite protocol and other very promising natural cancer therapies.
We also offer professional level nutraceutical products for clinical oncology.
Any individual seeking help with navigating through the maze of alternative cancer treatment options is invited to contact us for assistance. We offer personalized nutritional counseling services for cancer and other degenerative diseases. Initial consultations and referral services are free.
Thank you for visiting!
